Skip to main content
. Author manuscript; available in PMC: 2023 Mar 9.
Published in final edited form as: Expert Opin Investig Drugs. 2022 Aug 3;31(9):875–879. doi: 10.1080/13543784.2022.2108588

Figure 1. CD200AR-L extends survival.

Figure 1.

Following surgical resection of the tumors, serial vaccinations of autologous tumor lysate and canine-specific CD200AR-L were administered to each dog. Disease status was followed using magnetic resonance imaging (MRI). Peripheral Blood Mononuclear Cells were isolated at time of treatments and analyzed for (a) Tregs, Bregs, and MDSCs and (b) CD4+PD-1 and CD8+PD-1 T-cells.